Corrigendum to "Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations" [Eur J Cancer 207 (2024) 114158]
1 Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. Electronic address: [email protected].
2 Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
3 Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
4 Translational Oncology/Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken and Bavarian Cancer Research Center (BZKF), University Hospital Würzburg, Würzburg, Germany.
5 Department of Pathology, University Hospital Giessen and Marburg, Giessen, Germany.
6 Department of Pneumology, Heckeshorn Lung Clinic, Helios Klinikum Emil von Behring, Berlin, Germany.
7 Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universita¨t Erlangen-Nürnberg (FAU), Erlangen, Germany.
8 Department of Medical Oncology and Pneumology (Internal Medicine VIII), Eberhard Karls University, Tübingen, Germany.
9 Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany.
10 Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
11 Institute of Pathology, Charit´e - Universit¨atsmedizin Berlin, Berlin, Germany.
12 Institute of Pathology, University Hospital and Medical Faculty, University of Cologne, Cologne, Germany.
13 Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany.